Macroeconomic conditionspositive · 4 filings
“Trade tensions and conflicts between the U.S.”10-Q · May 7, 2026 ↗
Akebia Therapeutics, Inc.
AKBA
Market read
Akebia Therapeutics, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 33 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
Company+0.6% todayVolume comparison unavailable
Market group0 of 33 activeIndustrial Financials · unavailable
Disclosed network0 of 8 confirmingNo filing-linked name is confirming now
What would change this read
Watch this read- AKBA's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if AKBA's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 33 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
Evidence that supports
No thresholded supportive filing evidence is available yet.
Evidence that challenges
No thresholded adverse filing evidence is available yet.
What would clarify the read
- AKBA's market-adjusted activity becomes unusual and at least one connected name confirms.
Company research
Understand the business, not just the ticker
Business model and earnings drivers
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Key research questions
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
Annual periods9
Price observations320
Usable filing statements76
Verified relationships14
Evidence supporting the case
- Latest annual revenue changed +47.5% year over year.
- Operating margin changed +41.5 percentage points in the latest annual period.
- Net margin changed +41.1 percentage points in the latest annual period.
- Macroeconomic conditions has repeated favorable evidence across 4 filings.
Evidence challenging the case
- Diluted shares increased 21.9% in the latest annual period.
Questions before a position
- EV/sales is 76% below the available filing-peer median; determine whether growth and quality justify the difference.
Longer-term price context
Price as of Sep 11, 2026
0.956m-24.3%12m-69.5%24m—
Annual trajectory
Reported annual revenue and per-share history. This is accounting history, not a forecast.
PeriodRevenueYoYDiluted EPSShare change
2021-12-31$213.6M-27.7%$-1.70+19.9%
2022-12-31$292.5M+36.9%$-0.52+10.1%
2023-12-31$194.6M-33.5%$-0.28+2.6%
2024-12-31$160.2M-17.7%$-0.33+12.5%
2025-12-31$236.2M+47.5%$-0.02+21.9%
What management says matters
Persistent and emerging business drivers
Credit and interest ratesnegative · 1 filings
“The increase was primarily due to higher non-cash interest expense related to the settlement royalty liability in connection with the Vifor Termination Agreement, which we entered into in July 2024, partially offset by interest income related to our money mar…”10-K · Feb 26, 2026 ↗
Foreign exchangenegative · 1 filings
“Foreign Corrupt Practices Act, or FCPA , the UK Bribery Act or similar local regulation, the EU General Data Protection Regulation, or GDPR , and similar data protection laws, and tax, employment, immigration and labor laws; • economic weakness, including inf…”10-K · Feb 26, 2026 ↗
Input and raw-material costsnegative · 1 filings
“Foreign Corrupt Practices Act, or FCPA , the UK Bribery Act or similar local regulation, the EU General Data Protection Regulation, or GDPR , and similar data protection laws, and tax, employment, immigration and labor laws; • economic weakness, including inf…”10-K · Feb 26, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 1.0× · EV/sales 0.5×. Comparisons use only industry-matched filing peers.
Scenario scaffold
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
0.95+0.6% today
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for AKBA. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for AKBA. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind AKBA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
AMGNAmgen Inc.competitorMay 7, 2026 ▾
“Vafseo Competition Drugs that compete with Vafseo include Epogen® (epoetin alfa) and Aranesp® (darbepoetin alfa), both commercialized by Amgen, Procrit® (epoetin alfa) and Eprex® (epoetin alfa), commercialized by Johnson & Johnson in the U.S.”
FMSFresenius Medical Care AGcompetitorMay 7, 2026 ▾
“Auryxia Competition Hyperphosphatemia Competition Auryxia is competing in the hyperphosphatemia market in the U.S.”
Depended on by
UNCYUnicycive Therapeutics, Inc.competitorMar 30, 2026 ▾
“Our future success depends on our ability to demonstrate and maintain a competitive advantage with respect to the development and commercialization of oxylanthanum carbonate, and any other product or product candidate, including those that may be in-licensed…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 10 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AKBA is currently a Follower in the organic co-movement group Industrial Financials. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for AKBA; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.